Snapshot from Aug 25, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / Kowa (company)
Entity

Kowa (company)

Tracked across 2 events · 13 articles · First seen Apr 23, 2026 · Last active Aug 10, 2026

Sentiment
50
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (2)
4 60
Business
Nicox NCX 470 China Regulatory Feedback
Impact: Kowa (company) is NicOx's exclusive U.S. partner for NCX 470 and is expected to submit the New Drug Application for the drug in the U.S. in summer 2026. Kowa (company) bears the commercialization costs for its licensed territories.
Jun 18, 2026 · 7 articles
4 40
Regulatory
NCX 470 NDA submitted in China
NicOx announced that its exclusive licensee in China, Paragon Therapeutics, has submitted a New Drug Application (NDA) to the Chinese China — National Medical Products Administration (NMPA) for NCX 470, a novel nitric oxide-donating bimatoprost…
Impact: Kowa (company) is NicOx's partner for the rest of the world and recently submitted the U.S. NDA. Its regulatory progress is aligned with NicOx's commercialization strategy.
Aug 10, 2026 · 6 articles
Key Actions (1)
80 Kowa (company) submitted NDA United States — Food and Drug AdministrationNCX 470 NDA submitted in China
ERGEN INTELLIGENCE
Track Kowa (company) live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.